Keybank National Association OH Has $7.92 Million Stock Holdings in Astrazeneca Plc $AZN

Keybank National Association OH trimmed its holdings in Astrazeneca Plc (NYSE:AZN) by 25.7% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 40,168 shares of the company’s stock after selling 13,871 shares during the period. Keybank National Association OH’s holdings in Astrazeneca were worth $7,922,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of AZN. Natixis Advisors LLC lifted its holdings in Astrazeneca by 14.3% in the 3rd quarter. Natixis Advisors LLC now owns 2,100,390 shares of the company’s stock worth $161,142,000 after purchasing an additional 262,465 shares during the last quarter. Guardian Capital LP grew its holdings in Astrazeneca by 31.0% during the third quarter. Guardian Capital LP now owns 83,074 shares of the company’s stock valued at $6,373,000 after purchasing an additional 19,648 shares during the last quarter. Legacy Capital Group California Inc. acquired a new position in Astrazeneca during the third quarter valued at approximately $406,000. Focus Partners Advisor Solutions LLC raised its position in shares of Astrazeneca by 53.8% in the third quarter. Focus Partners Advisor Solutions LLC now owns 10,307 shares of the company’s stock valued at $875,000 after purchasing an additional 3,604 shares during the period. Finally, Integral Health Asset Management LLC raised its position in shares of Astrazeneca by 50.0% in the third quarter. Integral Health Asset Management LLC now owns 300,000 shares of the company’s stock valued at $23,016,000 after purchasing an additional 100,000 shares during the period. Institutional investors and hedge funds own 20.35% of the company’s stock.

Astrazeneca Stock Down 0.1%

AZN opened at $194.96 on Friday. Astrazeneca Plc has a 1-year low of $137.23 and a 1-year high of $212.71. The company has a current ratio of 0.91, a quick ratio of 0.71 and a debt-to-equity ratio of 0.52. The stock has a market capitalization of $302.36 billion, a price-to-earnings ratio of 29.27, a P/E/G ratio of 1.58 and a beta of 0.24. The business has a 50 day moving average of $183.96 and a 200-day moving average of $188.09.

Astrazeneca (NYSE:AZN) last announced its earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.52 by $0.06. The business had revenue of $15.29 billion for the quarter, compared to analyst estimates of $14.93 billion. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. As a group, sell-side analysts anticipate that Astrazeneca Plc will post 10.28 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on AZN. The Goldman Sachs Group reaffirmed a “buy” rating on shares of Astrazeneca in a report on Wednesday. Wall Street Zen upgraded shares of Astrazeneca from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. Sanford C. Bernstein reissued a “buy” rating on shares of Astrazeneca in a research report on Monday, May 4th. DZ Bank upgraded shares of Astrazeneca from a “neutral” rating to a “buy” rating in a report on Wednesday, April 29th. Finally, Morgan Stanley reaffirmed an “overweight” rating on shares of Astrazeneca in a research report on Wednesday, April 8th. Fourteen investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $205.33.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.